Vaccine Breakthrough Infections and SARS-CoV-2 Variants

Vaccine breakthrough infections occur when individuals contract SARS-CoV-2 despite completion of an authorised immunisation schedule. These events have risen in prominence as viral variants acquire mutations that partially evade antibody-mediated neutralisation. Key drivers include waning immunity over time, host factors such as age and comorbidity, and the emergence of variants of concern bearing spike-protein alterations. While most breakthrough cases remain mild or asymptomatic, they can sustain transmission and challenge the attainment of herd immunity. Surveillance of genomic changes, evaluation of neutralising antibody titres and real-world effectiveness against emerging lineages underpin strategies for booster deployment, vaccine redesign and the maintenance of non-pharmaceutical interventions.

Research from Nature Portfolio

During a surge driven by the Delta variant, a cohort study of fully vaccinated healthcare workers found that approximately one quarter developed serological evidence of infection within two months of their second dose. Despite robust anti-spike responses and preserved protection against severe disease, asymptomatic or mild infections were common, underscoring that ChAdOx1-nCoV19 maintains high efficacy for clinical endpoints but is insufficient to fully interrupt transmission in high-exposure settings.

Vaccine Breakthrough Infections and SARS-CoV-2 Variants publication trend

The graph below shows the total number of articles in vaccine breakthrough infections and sars-cov-2 variants across all publications each year (not limited to Nature Index journals).

Technical terms

Breakthrough infection: Occurrence of SARS-CoV-2 infection in an individual at least two weeks after completion of the recommended vaccine series.

Variant of concern (VOC): A viral lineage with mutations that increase transmissibility, disease severity, or immune evasion relative to the ancestral strain.

Neutralising antibody: An immunoglobulin that binds to viral surface proteins, preventing host cell entry and inhibiting infectivity.

Viral load: Quantity of viral RNA present in a biological specimen, often inferred from cycle threshold values in PCR assays.

Seroprevalence: Proportion of individuals in a population with detectable antibodies against a pathogen, indicative of past infection or vaccination.

References

1. High failure rate of ChAdOx1-nCoV19 immunization against asymptomatic infection in healthcare workers during a Delta variant surge. Nature Communications (2022).
2. SARS-COV-2 breakthrough infection and its covariates among healthcare providers of a hospital in Bangladesh during the omicron wave. Heliyon (2024).
3. SARS-CoV-2 breakthrough infections during the second wave of COVID-19 at Pune, India. Frontiers in Public Health (2023).
4. An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam. EClinicalMedicine (2021).